A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions

Healthy Participants

Interventions

DRUG

Nintedanib

Specified Dose on specified days

DRUG

BMS 986278

Specified dose on specified days

Trial Locations (1)

Local Institution - 0001, Lenexa